News Quantified

SYBX – synlogic, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Synlogic (NASDAQ:SYBX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

Synlogic (NASDAQ:SYBX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

Form 8-K SYNLOGIC, INC. For: Nov 21

Form ARS SYNLOGIC, INC. For: Dec 31

Form DEF 14A SYNLOGIC, INC. For: Dec 15

Form 4 SYNLOGIC, INC. For: Oct 29 Filed by: Dooley Mary Beth

Top News Gainers

6/12 Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic™ Medicines 25.2%

3/12 Q4/2019 12/31/2019 EPS -0.370 ZacksConsensus -0.440 ActVsEst 0.070 - Beat 14.4%

8/8 Q2/2019 6/30/2019 EPS 0.450 ZacksConsensus -0.500 ActVsEst 0.950 - Beat 9.2%

1/21 An Interview with Ginkgo’s Reshma Shetty On Co-Founding Synthetic Biology’s First Unicorn [Forbes] 7.8%

2/4 Form 4 SYNLOGIC, INC. For: Feb 03 Filed by: Burgess Michael F. 7.2%

11/13 Synlogic Inc (NASDAQ: SYBX) had its "overweight" rating re-affirmed by analysts at Piper Jaffray Companies. They now have a $7.00 price target on the stock, down previously from $10.00. 6.4%

9/6 Synlogic Inc (NASDAQ: SYBX) was given a new $10.00 price target on by analysts at Piper Jaffray Companies. They now have a "buy" rating on the stock. 5.9%

5/9 Q1/2019 3/31/2019 EPS -0.510 ZacksConsensus -0.540 ActVsEst 0.030 - Beat 5.7%

4/17 Form DEF 14A SYNLOGIC, INC. For: Jun 04 5.6%

9/18 Form 3 SYNLOGIC, INC. For: Sep 16 Filed by: Riese Richard J. 5.3%

Top News Decliners

8/20 Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia -21.7%

9/4 Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) -11.1%

3/11 Synlogic to Present at Chardan's Virtual Microbiome Medicines Summit -9.7%

5/12 Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.7%

6/5 Form 8-K SYNLOGIC, INC. For: Jun 05 -9.3%

9/30 Synlogic to Present at the Chardan 3rd Annual Genetic Medicines Conference -9.2%

8/10 Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -8.2%

3/18 Synlogic Inc (NASDAQ: SYBX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $1.75 price target on the stock. -7.8%

9/25 Form 4 SYNLOGIC, INC. For: Sep 23 Filed by: Riese Richard J. -7.8%

7/17 Synlogic Inc (NASDAQ: SYBX) was given a new $25.00 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. -6.9%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day